Smoking cessation and the incidence of pre-diabetes and type 2 diabetes: a cohort study

Boudec, Joana Le; Marques‐Vidal, Pedro; Cornuz, Jacques; Clair, Carole

doi:10.1016/j.jdiacomp.2015.10.005

Cited by 15 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite increasing evidence of the metabolic risks caused by the interplay between smoking and diabetes, prevalence of smoking remains high among people with diabetes. In a country such as Switzerland, it is estimated that 20.8% of people with diabetes are current smokers [13, 14].…”

Section: Introductionmentioning

confidence: 99%

Smoking in men and women with type 2 diabetes: A qualitative gender-sensitive exploration of barriers to smoking cessation among people with type 2 diabetes

2019

Self Cite

View full text Add to dashboard Cite

Objectives Despite growing evidence of the impact of smoking on diabetes complications, people with type 2 diabetes still smoke at high rates and little is known about the specific barriers to quit smoking in this group. The purpose of this article is to explore the perception of smoking, and motivation and barriers to quit among smokers with type 2 diabetes. This exploratory study will help designing a smoking cessation intervention tailored to the needs of people with type 2 diabetes. We hypothesize both that living with diabetes and gender may raise additional difficulties to quit smoking. Setting The qualitative exploratory research included ten in-depth semi-structured individual interviews and five focus groups conducted in an Ambulatory Care University Hospital in Switzerland. The thematic analysis was conducted with a gender-sensitive focus. Participants Both current and former smokers recruited from the ambulatory clinic and the community took part in the qualitative interviews. We restricted the analysis to 21 current smokers only. Results The sample included 12 men and 9 women with type 2 diabetes, having a mean age of 59.4 years, who had diabetes for an average of 9 years with a mean HbA1c of 7.4%. We found that harmful effects of tobacco were superficially understood, and participants used several patterns of thinking to minimize the risks. The relation between tobacco and diabetes was poorly known. Readiness to change was related to personal self-image and meaningful engagement in life and social relationships. Barriers could be organized into three groups: dependence, psychological habits and social barriers. Barriers were markedly shaped by gender and living with diabetes. Conclusions Results suggest that “one -fits-all” smoking cessation interventions do not satisfy the needs of type 2 diabetic smokers. Personalized smoking cessation interventions should be preferred and should pursue positive psychological outcomes addressing contextual factors.

show abstract

Section: Introductionmentioning

confidence: 99%

Smoking in men and women with type 2 diabetes: A qualitative gender-sensitive exploration of barriers to smoking cessation among people with type 2 diabetes

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, the future challenge is how to minimize the stunning phenomenon and maximize the preconditioning phenomenon in clinical practice. 45 Since smoking cessation has not been found associated with an increased risk of prediabetes or DM, 46 health professionals should strongly recommend smoking cessation with focus on limiting weight gain after quitting particularly in diabetic and prediabetic patients.…”

Section: Discussionmentioning

confidence: 99%

Non-infarct related chronically occluded coronary arteries and its association with diabetes and prediabetes

Karanfil¹,

Akdi²,

Özbay³

et al. 2019

Cor Vasa

View full text Add to dashboard Cite

Chronické totální uzávěry koronárních tepen (chronic coronary total occlusion, CTO) jsou většinou spojeny s infarktovou tepnou (infarct-related chronic coronary total occlusion, IRA CTO); ne všechny CTO však musejí vždy vést k rozvoji STEMI nebo být STEMI vyvolány. Klinický profi l pacientů s neinfarktovou CTO (non-IRA CTO) by mohl představovat endogenní kardioprotektivní mechanismus aktivovaný v odpověď na ischemii myokardu vyvolanou rozvojem aterosklerózy. Cíl: Naším cílem bylo posoudit klinický profi l pacientů s non-IRA CTO z hlediska přítomných faktorů kardiovaskulárního rizika. Metody: Prohlédli jsme naši databázi invazivních kardiologických výkonů, přičemž jsme pátrali po non-IRA CTO jakékoli významnější koronární tepny a snažili jsme se zjistit, zda byl v anamnéze pacienta uveden infarkt myokardu nebo zda byl nalezen elektrokardiografi cký (kmity Q, vymizení kmitu R), echokardiografi cký nebo ventrikulografi cký důkaz v tomto směru (abnormální kinetika segmentu stěny levé komory). Následně jsme porovnali incidenci non-IRA CTO u pacientů s diabetem, prediabetem a u kontrolních skupin jedinců bez diabetu nebo prediabetu. Výsledky: Popisujeme průřezovou studii s 2 180 pacienty, u nichž byla v období mezi lednem a dubnem 2018 v nemocnici terciární péče provedena koronarografi e pro zhodnocení stabilní ischemické choroby srdeční. Nalezli jsme 41 po sobě následujících pacientů s non-IRA CTO (1,9 %) s nízkou prevalencí kuřáctví (7 %). Většina jedinců s uvedeným nálezem (93 %) měla buď diabetes (61 %), nebo prediabetes (32 %); v tomto ohledu se statisticky významně lišili od jedinců bez diabetu nebo prediabetu (p < 0,001). Závěr: Nalezli jsme vztah mezi non-IRA CTO a prediabetem a diabetem. Zatímco diabetes a prediabetes agresivně vyvolávají aterosklerózu, mohou aktivovat i endogenní kardioprotektivní mechanismy chránící kontraktilní funkci levé komory.

show abstract

“…6 Despite the high rate of complications related to cigarette smoking, smoking prevalence remains high among people with diabetes. [19][20][21] Smoking cessation in people with diabetes It is a challenge for clinicians to induce a change in the behaviour of people with diabetes and to encourage a healthy lifestyle. 22 Smokers with diabetes might differ from other smokers regarding not only their risks, but also their reasons for smoking and motivations to quit.…”

Section: Open Accessmentioning

confidence: 99%

Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT)

Clair

Augsburger²,

Birrer

et al. 2020

BMJ Open

Self Cite

View full text Add to dashboard Cite

IntroductionFew studies have assessed the efficacy of smoking cessation interventions in individuals with type 2 diabetes, but interventions adapted to the specific needs of this population are warranted. The aim of this study is to assess the efficacy of a smoking cessation intervention in a population of smokers with type 2 diabetes and to measure the metabolic impact of smoking cessation.Methods and analysisThe study is an open-label, randomised control trial. Participants recruited from a sanitary region of Switzerland will be randomly allocated to either the intervention or the control arm. The intervention group will have four individual counselling sessions over 12 weeks. Trained research nurses will conduct the behavioural intervention, using motivational interviews and addressing diabetes and gender specificities. The control group will have one short counselling session at baseline and will be given written information on smoking cessation. Both groups will have a follow-up visit at 26 and 52 weeks. Demographic and medical data will be collected at baseline and follow-up, along with blood and urine samples. The primary study outcome is continuous smoking abstinence validated by expired-air carbon monoxide from week 12 to week 52. Secondary study outcomes are continuous and 7-day point prevalence smoking abstinence at 12 and 26 weeks; change in motivation to quit and cigarette consumption; and change in glycosylated haemoglobin levels, body weight, waist circumference and renal function after smoking cessation. In a subsample of 80 participants, change in stool microbiota from baseline will be measured at 3, 8 and 26 weeks after smoking cessation.Ethics and disseminationEthical approval has been obtained by the competent ethics committee (Commission cantonale d’éthique de la recherche sur l’être humain, CER-VD 2017–00812). The results of the study will be disseminated through publications in peer-reviewed journals and conference presentations.Trial registration numbersClinicalTrials.gov NCT03426423 and SNCTP000002762; Pre-results.

show abstract

Smoking cessation and the incidence of pre-diabetes and type 2 diabetes: a cohort study

Abstract: In this middle-aged population, smoking cessation was not associated with an increased risk of IFG or T2DM.

Cited by 15 publications

References 32 publications

Smoking in men and women with type 2 diabetes: A qualitative gender-sensitive exploration of barriers to smoking cessation among people with type 2 diabetes

Smoking in men and women with type 2 diabetes: A qualitative gender-sensitive exploration of barriers to smoking cessation among people with type 2 diabetes

Non-infarct related chronically occluded coronary arteries and its association with diabetes and prediabetes

Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT)

Contact Info

Product

Resources

About